The total number of records retrieved from this search are 24. Click on ID to see further detail.

ID	Virus name	Virus strain	Virus genome type	Virus family	Virus genome modification	Virus alone	Virus in combination with drug/radiation	Immune gene insertion in viral genome	Source of cell line	Origin of cell line	Cell line	Concentration of cell line	In-vitro toxicity	Assay	In-vitro virus concentration	In-vitro result	Model organism	In-vivo virus concentration	In-vivo toxicity	In-vivo result	Mode of delivery	Pathway induced	Immunogenic effect	Clinical trial	PMID
IDOV_2427	Virus nameVaccinia virus	Virus strainGLV-1h151	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeteltion of TK gene and addition of GFP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman squamous cell line	Cell lineSCC-25	Concentration of cell line3.0E+4 cells per well	In-vitro toxicityNA	AssayLDH release and spectrophometer	In-vitro virus concentration0.01 MOI	In-vitro result100% cell survival after day 1	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID22258815
IDOV_2428	Virus nameVaccinia virus	Virus strainGLV-1h151	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeteltion of TK gene and addition of GFP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman squamous cell line	Cell lineSCC-25	Concentration of cell line3.0E+4 cells per well	In-vitro toxicityNA	AssayLDH release and spectrophometer	In-vitro virus concentration0.01 MOI	In-vitro result100% cell survival after day 3	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID22258815
IDOV_2429	Virus nameVaccinia virus	Virus strainGLV-1h151	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeteltion of TK gene and addition of GFP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman squamous cell line	Cell lineSCC-25	Concentration of cell line3.0E+4 cells per well	In-vitro toxicityNA	AssayLDH release and spectrophometer	In-vitro virus concentration0.01 MOI	In-vitro result100% cell survival after day 5	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID22258815
IDOV_2430	Virus nameVaccinia virus	Virus strainGLV-1h151	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeteltion of TK gene and addition of GFP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman squamous cell line	Cell lineSCC-25	Concentration of cell line3.0E+4 cells per well	In-vitro toxicityNA	AssayLDH release and spectrophometer	In-vitro virus concentration0.01 MOI	In-vitro result50% cell killing after day 7	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID22258815
IDOV_2431	Virus nameVaccinia virus	Virus strainGLV-1h151	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeteltion of TK gene and addition of GFP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman squamous cell line	Cell lineSCC-25	Concentration of cell line3.0E+4 cells per well	In-vitro toxicityNA	AssayLDH release and spectrophometer	In-vitro virus concentration0.01 MOI	In-vitro result60% cell killing after day 9	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID22258815
IDOV_2467	Virus nameVaccinia virus	Virus strainGLV-1h151	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeteltion of TK gene and addition of GFP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman squamous cell line	Cell lineSCC-25	Concentration of cell line3.0E+4 cells per well	In-vitro toxicityNA	AssayLDH release and spectrophometer	In-vitro virus concentration0.10 MOI	In-vitro result100% cell survival after day 1	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID22258815
IDOV_2468	Virus nameVaccinia virus	Virus strainGLV-1h151	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeteltion of TK gene and addition of GFP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman squamous cell line	Cell lineSCC-25	Concentration of cell line3.0E+4 cells per well	In-vitro toxicityNA	AssayLDH release and spectrophometer	In-vitro virus concentration0.10 MOI	In-vitro result90% cell survival after day 3	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID22258815
IDOV_2469	Virus nameVaccinia virus	Virus strainGLV-1h151	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeteltion of TK gene and addition of GFP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman squamous cell line	Cell lineSCC-25	Concentration of cell line3.0E+4 cells per well	In-vitro toxicityNA	AssayLDH release and spectrophometer	In-vitro virus concentration0.10 MOI	In-vitro result50% cell survival after day 5	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID22258815
IDOV_2470	Virus nameVaccinia virus	Virus strainGLV-1h151	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeteltion of TK gene and addition of GFP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman squamous cell line	Cell lineSCC-25	Concentration of cell line3.0E+4 cells per well	In-vitro toxicityNA	AssayLDH release and spectrophometer	In-vitro virus concentration0.10 MOI	In-vitro result40% cell survival after day 7	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID22258815
IDOV_2471	Virus nameVaccinia virus	Virus strainGLV-1h151	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeteltion of TK gene and addition of GFP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman squamous cell line	Cell lineSCC-25	Concentration of cell line3.0E+4 cells per well	In-vitro toxicityNA	AssayLDH release and spectrophometer	In-vitro virus concentration0.10 MOI	In-vitro result30% cell survival after day 9	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID22258815
IDOV_2504	Virus nameVaccinia virus	Virus strainGLV-1h151	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeteltion of TK gene and addition of GFP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman squamous cell line	Cell lineSCC-25	Concentration of cell line3.0E+4 cells per well	In-vitro toxicityNA	AssayLDH release and spectrophometer	In-vitro virus concentration1 MOI	In-vitro result50% cell survival after day 1	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID22258815
IDOV_2505	Virus nameVaccinia virus	Virus strainGLV-1h151	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeteltion of TK gene and addition of GFP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman squamous cell line	Cell lineSCC-25	Concentration of cell line3.0E+4 cells per well	In-vitro toxicityNA	AssayLDH release and spectrophometer	In-vitro virus concentration1 MOI	In-vitro result20% cell survival after day 3	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID22258815
IDOV_2506	Virus nameVaccinia virus	Virus strainGLV-1h151	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeteltion of TK gene and addition of GFP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman squamous cell line	Cell lineSCC-25	Concentration of cell line3.0E+4 cells per well	In-vitro toxicityNA	AssayLDH release and spectrophometer	In-vitro virus concentration1 MOI	In-vitro result100% cell death after day 5	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID22258815
IDOV_2507	Virus nameVaccinia virus	Virus strainGLV-1h151	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeteltion of TK gene and addition of GFP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman squamous cell line	Cell lineSCC-25	Concentration of cell line3.0E+4 cells per well	In-vitro toxicityNA	AssayLDH release and spectrophometer	In-vitro virus concentration1 MOI	In-vitro result100% cell death after day 7	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID22258815
IDOV_2508	Virus nameVaccinia virus	Virus strainGLV-1h151	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeteltion of TK gene and addition of GFP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman squamous cell line	Cell lineSCC-25	Concentration of cell line3.0E+4 cells per well	In-vitro toxicityNA	AssayLDH release and spectrophometer	In-vitro virus concentration1 MOI	In-vitro result100% cell death after day 9	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID22258815
IDOV_2978	Virus nameReovirus	Virus strainwild type	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman neck and squamous carcinoma cell line	Cell lineSCC-25	Concentration of cell line7.68E+3 cells per well	In-vitro toxicityNA	AssayAlamar blue assay	In-vitro virus concentration2.4 × 10⁸ pfu	In-vitro result54.6 +/- 21.5% cell viable after 96 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID25890191
IDOV_4670	Virus nameHerpes simplex virus	Virus strainRAMBO	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationAntiangiogenic Vstat120 expressing virus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman squamous cell carcinoma cell line	Cell lineUD-SCC-2	Concentration of cell lineNA	In-vitro toxicityNA	AssayStatistical analysis	In-vitro virus concentration0.001 MOI	In-vitro result100% cell viability after 2 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduce antitumor immune response	Clinical trialNA	PMID27119105
IDOV_4671	Virus nameHerpes simplex virus	Virus strainRAMBO	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationAntiangiogenic Vstat120 expressing virus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman squamous cell carcinoma cell line	Cell lineUD-SCC-2	Concentration of cell lineNA	In-vitro toxicityNA	AssayStatistical analysis	In-vitro virus concentration0.005 MOI	In-vitro result95% cell viability after 2 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduce antitumor immune response	Clinical trialNA	PMID27119105
IDOV_4672	Virus nameHerpes simplex virus	Virus strainRAMBO	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationAntiangiogenic Vstat120 expressing virus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman squamous cell carcinoma cell line	Cell lineUD-SCC-2	Concentration of cell lineNA	In-vitro toxicityNA	AssayStatistical analysis	In-vitro virus concentration0.01 MOI	In-vitro result90% cell viability after 2 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduce antitumor immune response	Clinical trialNA	PMID27119105
IDOV_4673	Virus nameHerpes simplex virus	Virus strainRAMBO	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationAntiangiogenic Vstat120 expressing virus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman squamous cell carcinoma cell line	Cell lineUD-SCC-2	Concentration of cell lineNA	In-vitro toxicityNA	AssayStatistical analysis	In-vitro virus concentration0.05 MOI	In-vitro result40% cell viability after 2 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduce antitumor immune response	Clinical trialNA	PMID27119105
IDOV_4674	Virus nameHerpes simplex virus	Virus strainRAMBO	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationAntiangiogenic Vstat120 expressing virus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman squamous cell carcinoma cell line	Cell lineUD-SCC-2	Concentration of cell lineNA	In-vitro toxicityNA	AssayStatistical analysis	In-vitro virus concentration0.1 MOI	In-vitro result25% cell viability after 2 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduce antitumor immune response	Clinical trialNA	PMID27119105
IDOV_4675	Virus nameHerpes simplex virus	Virus strainRAMBO	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationAntiangiogenic Vstat120 expressing virus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman squamous cell carcinoma cell line	Cell lineUD-SCC-2	Concentration of cell lineNA	In-vitro toxicityNA	AssayStatistical analysis	In-vitro virus concentration0.5 MOI	In-vitro result22% cell viability after 2 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduce antitumor immune response	Clinical trialNA	PMID27119105
IDOV_4676	Virus nameHerpes simplex virus	Virus strainRAMBO	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationAntiangiogenic Vstat120 expressing virus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman squamous cell carcinoma cell line	Cell lineUD-SCC-2	Concentration of cell lineNA	In-vitro toxicityNA	AssayStatistical analysis	In-vitro virus concentration1 MOI	In-vitro result20% cell viability after 2 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduce antitumor immune response	Clinical trialNA	PMID27119105
IDOV_4702	Virus nameHerpes simplex virus	Virus strainRAMBO	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationAntiangiogenic Vstat120 expressing virus	Virus aloneNo	Virus in combination with drug/radiationVirus combination with ATN-224 (8 micromolar/litre) an copper chelator show synergy	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman squamous cell carcinoma cell line	Cell lineSCC-2	Concentration of cell lineNA	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration0.5 MOI	In-vitro result45% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduce antitumor immune response	Clinical trialNA	PMID27119105